[An unusual cause of peritonitis].

F. Klein,F. Mícek

Zentralblatt für Chirurgie

Abstract:

What problem does this paper attempt to address?

[The determination of opium alkaloids with thin layer and high pressure liquid chromatography].

E. Stahl,H. Jahn

DOI: https://doi.org/10.1016/0378-8741(86)90145-5

1986-09-01

Pharmaceutica Acta Helvetiae

Abstract:
Androgens, cardiovascular disease and osteoporosis

A M Isidori,E Giannetta,C Pozza,V Bonifacio,A Isidori

Abstract:Epidemiological studies correlated the age-related decline of serum testosterone levels to the concomitant increase of cardiovascular diseases, osteoporosis and bone fractures. For this reason, testosterone replacement therapy (TRT) in older men with late-onset hypogonadism has been advocated. Testosterone has an anti-resorptive effect that may increase bone density at lumbar spine. Androgens may also have cardio-protective effects by improving endothelial function and reducing the risk factors for atherosclerosis. It has been proposed that atherosclerosis and osteoporosis share common pathophysiological mechanisms. The role of inflammatory cells, citokynes and calcium deposition into the vascular walls has been reviewed to explore the causal nexus between these frequently associated diseases. Experimental studies indicate that a deregulation in the commitment of pluripotent mesenchimal stem cells toward specialized phenotypes might participate in the development of these conditions. The crossed-over beneficial effect of bisphosphonate on the cardiovascular system and statins on bone metabolism supports the research for a unitary pharmacological approach to both conditions. The findings that androgens regulate mesenchimal cell differentiation, as well as body composition, lipid profile and bone metabolism, have claimed a role for TRT in aging men with late onset-hypogonadism.
The durability and distribution of glass fibres in the rat following intra-peritoneal injection.

C. Collier,K. J. Morris,K. Launder,J. Humphreys,A. Morgan,W. Eastes,Stuart Townsend

DOI: https://doi.org/10.1016/0003-4878(95)00010-C

1995-10-01

Abstract:
Association of Estrogen Receptor α and Vitamin D Receptor Gene Polymorphisms with Bone Mineral Density in Chinese Males

J. R. Long,Y. Y. Zhang,P. Y. Liu,Y. J. Liu,H. Shen,V. Dvornyk,L. J. Zhao,H. W. Deng

DOI: https://doi.org/10.1007/s00223-003-0087-4

2003-01-01

Calcified Tissue International

Abstract:Osteoporosis is a common health problem not only in females but also in males, however, studies of osteoporosis in males are relatively rare compared to those in females. This is especially true in genetics studies. We evaluated the effects of Pvu II and Xba I polymorphisms in the estrogen receptor α (ER-α) gene and Apa I polymorphism in the vitamin D receptor (VDR) gene on BMD variation in a random sample of 352 unrelated males from 401 Chinese nuclear families. BMD was measured at the lumbar spine (L1–L4) and hip (femoral neck, trochanter, intertrochanteric region). Raw BMD values were adjusted by age, age 2 , height, and weight as covariates. We found no significant results for the 3 individual markers on BMD variation, however, ER-α haplotype analyses yielded some interesting results. Carriers of haplotype pX had a 4.98% lower BMD at the trochanter ( P = 0.02) and 3.55% lower BMD at the lumbar spine ( P = 0.09) than non-carriers. PX subjects had a 3.42% higher BMD at the trochanter and 3.26% higher BMD at the lumbar spine than others ( P = 0.07 and P = 0.10, respectively). Such results were highly comparable with the significant or nearly significant interactions between ER- Pvu II and ER- Xba I on BMD values at the trochanter ( P = 0.03) and spine ( P = 0.11). No significant results were observed for the interactions between ER- Pvu II and VDR- Apa I, between ER- Xba I and VDR- Apa I, and between any of ER-α haplotypes and VDR- Apa I locus. Our results suggest that the ER-α haplotypes, not individual markers, may be associated with BMD variation at some skeletal sites in our Chinese male samples.
Biochemical characterisation of Francisella tularensis strains isolated in Spain

N. García del Blanco,C. B. Gutiérrez,V. A. De La Puente,E. R. Rodríguez Ferri

DOI: https://doi.org/10.1136/vr.154.2.55

2004-01-10

Abstract:Correspondence to Dr Rodriguez Ferri BRAUN, U., AMREIN, E., ESTERMANN, U., EGLI, J., SCHWEIZER, T., LUTZ, H., EHRENSPERGER, F., VANDEVELDE, M. & KIHM, U. (1998) Untersuchungen an 182 Nachkommen von an boviner spongiformer Enzephalopathie (BSE) erkrankten Kuhen in der Schweiz. Teil 1: Klinische Befunde. Schweizer Archivfiir Tierheilkunde 140, 241-249 BRAUN, U., FLOCKIGER, M., GERSPACH, C. & GREST, P. (2003a) Clinical and radiographic findings in six cattle with cervical diskospondylitis. Veterinary Record 152, 630-632 BRAUN, U., GERSPACH, C., SALIS, F. & FEIGE, K. (2003b) Klinische Befunde bei 4 Rindern mit Abszess in der Halswirbelsaule. Schweizer Archiv fur Tierheilkunde 145, 124-128 BRAUN, U., HERMANN, M. & PABST, B. (1989) Haematological and biochemical findings in cattle with dilatation and torsion of the caecum. Veterinary Record 125, 396-398 BRAUN, U., SCHWEIZER, G., GERSPACH, C. & FEIGE, K. (2003c) Clinical findings in 11 cattle with abscesses in the thoracic vertebrae. Veterinary Record 152, 782-784 COOPER, J. & WALKER, R. D. (1998) Listeriosis. Veterinary Clinics ofNorth America: Food Animal Practice 14, 113-125 DENNIS, S. M. (1993) Listeriosis (circling disease, silage sickness). In Current Veterinary Therapy, Food Animal Practice. Philadelphia, W. B. Saunders. pp 580-583 EHRENSPERGER, F., HILBE, M., SYDLER, T., CORBOZ, L., BRAUN, U. & POSPISCHIL, A. (2001) Zerebrale Listeriose bei Schaf und Ziege: eine histopathologische und immunhistologische Studie. Wiener Tieriirztliche Monatsschrift 88, 219-225 GATES, G. A., BLENDEN, D. C. & KINTNER, L. D. (1967) Listeric myelitis in sheep. Journal of the American Veterinary Medical Association 150, 200-204 KLEE, W. (1987) Diagnose und Therapie der Listeriose beim Rind. Praktischer Tierarzt 68, 53-54 STOBER, M. & GRUNDER, H-D. (1990) Die klinische Untersuchung des Rindes. 3rd edn. Eds G. Dirksen, H-D. Grunder, M. Stober. Berlin, Munchen, Paul PareyVerlag. pp 203-230 SEAMAN, J. T., CARTER, G. I., CARRIGAN, M. J. & COCKRAM, F. A. (1990) An outbreak of listerial myelitis in sheep. Australian Veterinary Journal 67, 142143
Early effects of androgen deprivation on bone and mineral homeostasis in adult men: a prospective cohort study.

Rougin Khalil,Leen Antonio,Michaël R Laurent,Karel David,Na Ri Kim,Pieter Evenepoel,Anton Eisenhauer,Alexander Heuser,Etienne Cavalier,Sundeep Khosla,Frank Claessens,Dirk Vanderschueren,Brigitte Decallonne

DOI: https://doi.org/10.1530/EJE-20-0348

2020-05-27

European Journal of Endocrinology

Abstract:Objective: Long-term androgen deprivation therapy (ADT) negatively influences bone. The short-term effects on bone and mineral homeostasis are less known. Therefore, we aimed to investigate the early effects of ADT on calcium/phosphate homeostasis and bone turnover. Design: Prospective cohort study Methods: Eugonadal adult male sex offenders, who were referred for ADT to the endocrine outpatient clinic, received cyproterone acetate. Changes in blood markers of calcium/phosphate homeostasis and bone turnover between baseline and first follow-up visit were studied. Results: Of 26 screened patients, 17 were included. The median age was 44 (range 20-75) years. The median time interval between baseline and first follow-up was 13 (6-27) weeks. Compared to baseline, an 81% decrease was observed for median total testosterone (to 3.4 nmol/L (0.4-12.2); P<0.0001) and free testosterone (to 0.06 nmol/L (0.01-0.18); P<0.0001). Median total estradiol decreased 71% (to 17.6 pmol/L (4.7-35.6); P<0.0001). Increased serum calcium (P<0.0001) and phosphate (P=0.0016) was observed, paralleled by decreased PTH (P=0.0156) and 1,25-dihydroxyvitamin D3 (P=0.0134). The stable calcium isotope ratio (δ44/42Ca) decreased (P=0.0458), indicating net calcium loss from bone. Bone-specific alkaline phosphatase and osteocalcin decreased (P<0.0001 and P=0.0056, respectively), periostin tended to decrease (P=0.0500) whereas sclerostin increased (P<0.0001), indicating suppressed bone formation. Serum bone resorption markers (TRAcP5b, CTX) were unaltered. Conclusions: In adult men, calcium release from the skeleton occurs early following sex steroid deprivation, reflecting early bone resorption. The increase of sclerostin and reduction of bone formation markers, without changes in resorption markers, suggests a dominant negative effect on bone formation in the acute phase.

endocrinology & metabolism
Molecularly imprinted adsorbents for positional isomer separation.

V. Joshi,M. Kulkarni,R. Mashelkar

DOI: https://doi.org/10.1016/S0021-9673(99)00477-X

IF: 4.601

1999-07-23

Journal of Chromatography A

Abstract:
Osteoporosis in men: the value of laboratory testing

C. S. Ryan,V. I. Petkov,R. A. Adler

DOI: https://doi.org/10.1007/s00198-010-1421-0

2010-10-09

Osteoporosis International

Abstract:Evaluation of 234 men referred for osteoporosis found many with undiagnosed secondary causes and multiple unrecognized risk factors.IntroductionStudies in women with postmenopausal osteoporosis suggest that many have unrecognized disorders affecting bone. Men are considered more likely to have underlying, possibly correctable causes. We studied the prevalence of risk factors, secondary causes, and laboratory abnormalities in men with and without previously known causes for osteoporosis.MethodsWe reviewed the charts of 234 men with osteoporosis diagnosed by bone mineral density testing. In addition to screening chemistries, 25-hydroxyvitamin D, testosterone, luteinizing hormone, follicle-stimulating hormone, thyroid-stimulating hormone, and spot urinary calcium-to-creatinine ratio were measured.ResultsThe mean age was 70.6 years and mean weight was 76.4 kg. The mean T-score for spine, femoral neck, and forearm was −2.2, −2.4, and −2.3, respectively. Evaluation revealed secondary osteoporosis in 75% overall including hypogonadism, vitamin D deficiency, hypercalciuria, subclinical hyperthyroidism, and hyperparathyroidism. In those men with known secondary osteoporosis at the time of dual energy X-ray absorptiometry testing, additional diagnoses were found in just over half. Vitamin D deficiency and insufficiency were very common, and other common risk factors for osteoporosis included age >65, current smoking, and prior fracture. Half of the subjects had ≥4 risk factors.ConclusionEvaluation revealed a specific cause in about half of men thought to have primary osteoporosis. Among men with known secondary osteoporosis, additional risk factors and secondary causes were frequently identified. In conclusion, a relatively modest evaluation of men with osteoporosis will often provide useful information.

endocrinology & metabolism
Osteoporosis from an Endocrine Perspective: The Role of Hormonal Changes in the Elderly

Rossella Cannarella,Federica Barbagallo,Rosita A. Condorelli,Antonio Aversa,Sandro La Vignera,Aldo E. Calogero

DOI: https://doi.org/10.3390/jcm8101564

IF: 3.9

2019-10-01

Journal of Clinical Medicine

Abstract:Introduction: Osteoporosis is increasingly prevalent in the elderly, with fractures mostly occurring in women and men who are older than 55 and 65 years of age, respectively. The aim of this review was to examine the evidence regarding the influence of hormones on bone metabolism, followed by clinical data of hormonal changes in the elderly, in the attempt to provide possible poorly explored diagnostic and therapeutic candidate targets for the management of primary osteoporosis in the aging population. Material and methods: An extensive Medline search using PubMed, Embase, and Cochrane Library was performed. Results: While the rise in Thyroid-stimulating hormone (TSH) levels has a protective role on bone mass, the decline of estrogen, testosterone, Insulin-like growth factor 1 (IGF1), and vitamin D and the rise of cortisol, parathyroid hormone, and follicle-stimulating hormone (FSH) favor bone loss in the elderly. Particularly, the AA rs6166 FSH receptor (FSHR) genotype, encoding for a more sensitive FSHR than that encoded by the GG one, is associated with low total body mass density (BMD), independently of circulating estrogen. A polyclonal antibody with a FSHR-binding sequence against the β-subunit of murine FSH seems to be effective in ameliorating bone loss in ovariectomized mice. Conclusions: A complete hormonal assessment should be completed for both women and men during bone loss evaluation. Novel possible diagnostic and therapeutic tools might be developed for the management of male and female osteoporosis.

medicine, general & internal
Short-Term Changes in Bone Metabolism Among Transgender Men Starting Gender-Affirming Hormone Therapy: A Systematic Review and Meta-analysis

Daniele Tienforti,Lorenzo Marinelli,Jeroen Vervalcke,Luca Spagnolo,Federica Antolini,Andreina Bichiri,Marco Giorgio Baroni,Giovanna Motta,Guy T’Sjoen,Arcangelo Barbonetti

DOI: https://doi.org/10.1007/s00223-024-01296-z

2024-10-03

Calcified Tissue International

Abstract:Transgender and gender diverse individuals experience a gender identity that differs from the sex assigned at birth. Some transgender men may request testosterone to induce virilization; however, its impact on bone health remains to be fully elucidated. The objective of this systematic review and meta-analysis was to evaluate the modifications in bone metabolism over a short-term period among transgender men initiating testosterone therapy. A systematic search was conducted in PubMed, Scopus, Web of Science, and Cochrane Library. The articles of interest had to report longitudinal evaluation conducted among transgender men, before starting testosterone and after 12 and 24 months of therapy. The analyzed parameters were BMD, calcium, phosphate, 25OHD, PTH, P1NP, BAP, osteocalcin and CTx. Mean differences with 95% coefficient intervals were combined using random effects models. Funnel plot, Egger's test, and trim-and-fill analysis were used to assess publication bias. Fourteen studies met the inclusion criteria, including 1484 subjects. In absence of heterogeneity, BMD did not significantly change at lumbar spine, hip, femoral neck, and whole-body evaluations. Calcium, phosphate, 25OHD and PTH remained stable over time. Regarding bone turnover markers, only P1NP showed a statistically significant increase after 12 months of T therapy, in absence of heterogeneity (SMD 0.61 mcg/l; 95% CI: 0.40–0.83; p < 0.0001; I 2 = 0%, P forheterogeneity = 0.48). Testosterone therapy among transgender men seems not to disrupt bone health after 12 and 24 months. A statistically significant elevation in P1NP levels after 12 months of therapy may indicate a positive anabolic effect of testosterone in the short-term.

endocrinology & metabolism
Demonstrating Adherence to Guidelines for the Treatment of Patients with Borderline Personality Disorder

N. Kolla,P. Links,S. McMain,D. Streiner,R. Cardish,Michele R. Cook

DOI: https://doi.org/10.1177/070674370905400306

2009-03-01

Abstract:Objective: To describe the development and implementation of General Psychiatric Management (GPM), a dynamically informed psychotherapeutic and case management approach along with symptom-targeted pharmacological interventions for the treatment of borderline personality disorder (BPD), derived from the American Psychiatric Association's (APA) guidelines for treating BPD. Method: Clinician adherence to GPM was assessed using the General Psychiatric Management Adherence Scale (GPMAS), which measured the amount of emphasis accorded to therapeutic tools and strategies during individual therapy sessions. GPMAS surveys were completed by 9 different therapists every 6 weeks during 1 year for 50 patients. Results: GPMAS displayed excellent internal consistency and good-to-excellent test–retest reliability. The convergence between patient- and therapist-rated sessions was excellent. Mean levels of emphasis were significantly greater for GPM interventions than prohibited ones across all time points. The mean number of prescribed psychotropic medications was 2.3, and the most frequently prescribed class of medication was antidepressants, followed by neuroleptics. Conclusions: From these results, we conclude that the clinicians were adherent to the outlined protocol and that the GPMAS is a valuable measure for demonstrating adherence to therapies based on the APA guidelines.
The Effects of Testosterone on Bone Health in Males with Testosterone Deficiency: a Systematic Review and Meta-Analysis

Zhichao Zhang,Deying Kang,Hongjun Li

DOI: https://doi.org/10.1186/s12902-020-0509-6

2020-01-01

BMC Endocrine Disorders

Abstract:BACKGROUND:Testosterone deficiency (TD) may induce a series of clinical symptoms. Studies have shown that testosterone supplementation may prevent these unfavourable symptoms and improve patients' quality of life. Given the conflicting findings across studies, this systematic review aims to evaluate the effects and risks associated with testosterone supplementation in middle-aged or aging males with TD.METHODS:Electronic databases (MEDLINE, EMBASE, PubMed, and Cochrane. Library were searched to December 2019. The risk of bias of individual included studies and the quality of the aggregate evidence were assessed using the GRADE approach. Our primary outcome was bone mineral density (BMD). Meta-analyses were performed. This systematic review was reported according to the PRISMA statement.RESULTS:A total of 52 randomized controlled trials (RCTs) were included. When compared with placebo, testosterone supplementation did not increase total BMD (short-term: 1081 participants, MD - 0.01 g/cm2, 95% CI - 0.02 g/cm2 to 0.01 g/cm2; long-term: 156 participants, MD 0.04 g/cm2, 95% CI - 0.07 g/cm2 to 0.14 g/cm2), lumbar spine, hip, or femur neck BMD. Furthermore, testosterone supplementation did not decrease the risk of falling or fracture. Lastly, it was found that testosterone supplementation did not increase the risk of cardiovascular events (1374 participants, RR 1.28, 95% CI 0.62 to 2.64), all-cause mortality (729 participants, RR 0.55, 95% CI 0.29 to 1.04), or prostatic events. However, testosterone supplementation may improve sexual function and quality of life (1328 participants, MD -1.32, 95% CI - 2.11 to - 0.52).CONCLUSIONS:The effect of testosterone supplementation on BMD and the risk of falls or fracture remains inconclusive. However, supplementation may benefit patients in the areas of sexual function and quality of life without increasing the risk of cardiovascular events, all-cause mortality, or prostatic events. RCTs with a longer follow-up period are still required.TRIAL REGISTRATION:We registered our protocol in PROSPERO (CRD42018109738).
The Imbalance of Cytokines and Lower Levels of Tregs in Elderly Male Primary Osteoporosis

Wei Zhang,Wei Zhao,Wei Li,Qi Geng,Rui Zhao,Yungui Yang,Luyan Lv,Weiwen Chen

DOI: https://doi.org/10.3389/fendo.2022.779264

IF: 6.055

2022-06-01

Frontiers in Endocrinology

Abstract:Introduction: Osteoporosis (OP) is a debilitating disease that brings a heavy burden to individuals and society with reduced quality of life and lifespan. However, it's frequently overlooked and poorly studied in elderly male patients. Worse still, few anti-osteoporosis drugs are effective at the prevention and treatment of osteoporosis in men. It has been reported that the cells of bone and the immune system share common progenitors, cytokines and growth factors, and that reciprocal interactions occur during health and disease. Nevertheless, the role of immune system in OP is not fully understood, especially in male patients. Therefore, this study aimed to investigate molecular alterations in immune cells in men with OP and to identify immunomodulatory strategies with potential therapeutic value. Materials and Methods: A population of 121 men aged between 51 and 80 years old was recruited. Bone mineral density (BMD) was measured at the lumbar spine L1-4 and femoral neck using dual-energy X-ray absorptiometry (DXA). Twenty people were healthy, 66 people had osteopenia and 35 people had OP. Bone metabolic markers, Th1, Th2, Tregs and immune molecules were evaluated at the time of enrollment. Results: Smoking was a risk factor for OP. C-terminal crosslinking of type I collagen (β-CTX) and the ratio of receptor activator of nuclear factor-κB ligand (RANKL) to osteoprotegerin (OPG) were higher in OP group, which had lower 25-hydroxyvitamin D [25(OH)D] levels. OP had the higher levels of IL-6 and TNF-α and lower levels of IFN-γ and IL-10. CD4 + CD25 + CD127 -/low Tregs were significantly lower in the OP group. The imbalance of Th1/Th2 cells may play an important role in the development of OP. 25(OH)D may play essential roles in maintaining bone health. The low level of Tregs is also one of the underlying immune mechanism that leads to male primary OP. Conclusion: The active function of osteoclasts and the decline in osteoblasts were characteristics of OP, and the imbalance in cytokines and lower levels of Tregs were observed in elderly male patients with primary OP.

endocrinology & metabolism
EMAS position statement: Testosterone replacement therapy in older men

George A Kanakis,Riccardo Pofi,Dimitrios G Goulis,Andrea M Isidori,Eleni Armeni,C Tamer Erel,Ivan Fistonić,Timothy Hillard,Angelica-Lindén Hirschberg,Blazej Meczekalski,Nicolás Mendoza,Alfred O Mueck,Tommaso Simoncini,Petra Stute,Dorenda van Dijken,Margaret Rees,Irene Lambrinoudaki

DOI: https://doi.org/10.1016/j.maturitas.2023.107854

IF: 5.11

Maturitas

Abstract:Introduction: Late-onset hypogonadism is the clinical entity characterised by low testosterone concentrations associated with clinical symptoms in the absence of organic disease in ageing men. It has been associated with metabolic syndrome, reduced bone mineral density, and increased cardiovascular morbidity and mortality risk. Although testosterone replacement therapy (TRT) reverses most of these conditions in young hypogonadal men, the risk/benefit ratio of TRT in older men is debatable. Aim: To update the 2015 EMAS statement on TRT in older men with new research on late-onset hypogonadism and TRT. Materials and methods: Literature review and consensus of expert opinion. Summary recommendations: TRT should be offered only to symptomatic older men with confirmed low testosterone concentrations after explaining the uncertainties regarding the long-term safety of this treatment. TRT may be offered to men with severe hypogonadism and erectile dysfunction to improve sexual desire, erectile, and orgasmic function. It should also be considered in hypogonadal men with severe insulin resistance or pre-diabetes mellitus. TRT may also be considered, in combination with proven treatment strategies, for osteoporosis, or for selected patients with persistent mild depressive symptoms and/or low self-perceived quality of life, combined with standard medical care for each condition. TRT is contraindicated in hypogonadal men actively seeking fertility treatment. Due to a lack of data, TRT should not be routinely used in older men to improve exercise capacity/physical function, improve cognitive function, or prevent cognitive decline. TRT must be avoided in older, frail men with known breast cancer or untreated prostate cancer and all men who have had myocardial infarction or stroke within the last four months, and those with severe or decompensated heart failure. The quality of evidence regarding patients with previous prostate cancer or cardiovascular disease is too low to draw definitive conclusions. Any limits on duration of use are arbitrary, and treatment should continue for as long as the man feels the benefits outweigh the risks for him, and decisions must be made on an individual basis. Withdrawal should be considered when hypogonadism is reversed after the resolution of underlying disorder. Short-acting transdermal preparations should be preferred for TRT initiation in older men, but injectable forms may be considered subsequently. Older men on TRT should be monitored at 3, 6, and 12 months after initiation and at least yearly thereafter, or earlier and more frequently if indicated. Evaluation should include assessment of the clinical response, and measurement of total testosterone, haematocrit, and prostate-specific antigen (PSA) concentrations. Bone density and/or quality should also be assessed. Obese and overweight patients should be encouraged to undergo lifestyle modifications, including exercise and weight loss, to increase endogenous testosterone.
(330) Testosterone Replacement Therapy in Hypogonadism: A Single Center Longitudinal Analysis of Treatment Patterns and Clinical Outcomes

A Iacobucci,T Naeem,G Saffati,Q Gadiwalla,N Mody-Bailey,C Green,LI Lipshultz,M Khera

DOI: https://doi.org/10.1093/jsxmed/qdae001.315

2024-02-01

The Journal of Sexual Medicine

Abstract:Abstract Introduction Male hypogonadism impacts the production of hormone production, which plays a key role in masculine growth. It has also been shown to impair certain male reproductive functions or delay development. Objective The goal of this study is to describe the characteristics and treatment outcomes for patients with a diagnosis of Hypogonadism (HG) presenting to an academic urology center. Methods An IRB was approved to conduct a longitudinal study on the outcomes of male hypogonadism at a high-volume tertiary referral center. Men diagnosed with hypogonadism were identified by ICD 10 code (E 29.1). Clinical, demographic, laboratory, and testosterone replacement therapy and outcomes were extracted from the EMR. Results This retrospective study included 537 patients with a median age of presentation of 52 years (IQR: 42-68). At the initial visit, 66% presented with low libido, 65% with erectile dysfunction (ED), and 6% with depression. On initial hormonal evaluation, median (IQR) measurements for testosterone, free testosterone, and estradiol were 294 (217.5-417), 6.1 (4.45-8.0), and 4 (2-17) respectively. 227 (56.5%) patients elected to begin Testosterone Replacement Therapy (TRT). Of these, five treatment types of TRT were observed: 114 (53%) patients elected for intramuscular TRT, 25 (12%) utilized a pellet implant, 74 (34%) utilized topical treatment TRT, 3 (1.4%) used pellet and topical, and 1 (0.5%) used topical and intramuscular. Following TRT, 143 (79%) patients endorsed an improvement in ED, 175 (84%) reported improved libido, 176 (84%) reported increased energy levels, and 88 (59%) showed improvement in muscle mass. Follow-up labs measuring testosterone, free testosterone, and estradiol demonstrated medians of 486 (IQR: 296.5-802.8), 15.3 (IQR: 6.9-88.7), and 16.45 (IQR: 3-28.85) respectively. Adverse events while on TRT were 32 (15%) polycythemia, 3 (1.4%) VTE’s, and 3 (1.4%) MI. Conclusions Sexual dysfunction is a prominent symptom encountered by men with hypogonadism. However, only 56.5% of hypogonadal men pursue TRT, with intramuscular injections being the most commonly prescribed formulation. In our longitudinal cohort, we report that polycythemia and cardiovascular events are uncommon sequela after TRT. Further randomized control trials are warranted to better understand cardiovascular events' association with TRT. Disclosure Any of the authors act as a consultant, employee or shareholder of an industry for: Consultant for AbbVie, Marius, Tolmar, Endo, Petros, Boston Scientific, Coloplast Investor: Sprout.

urology & nephrology
Impact of testosterone treatment on circulating irisin in men with late-onset hypogonadism and metabolic syndrome

Yavor Assyov,Antoaneta Gateva,Vera Karamfilova,Tsvetan Gatev,Iveta Nedeva,Tsvetelina Velikova,Zdravko Asenov Kamenov

DOI: https://doi.org/10.1080/13685538.2020.1770721

2020-05-26

The Aging Male

Abstract:Objectives: The beneficial effects of testosterone replacement therapy (TRT) in men with late-onset hypogonadism (LOH) on the body composition and metabolic outcomes are well-established. A potential explanation might lie in the hormones, secreted from skeletal muscles, named "myokines". The aim of this study was to evaluate the effects of TRT on the levels of serum irisin in subjects with LOH.Study Design: A total 40 men with metabolic syndrome (MS) and LOH (measured serum testosterone concentration < 12 nmol/l). TRT with Testosterone Undecanoate (Nebido™) was performed at baseline and at week 6. Irisin serum concentration was determined at baseline and at week 18 by means of ELISA.Results: Circulating irisin was positively associated with serum testosterone (r = 0.283, p < 0.05). TRT has led to a statistically significant rise in circulating serum irisin levels (7.12 ± 0.76 mcg/ml versus 7.76 ± 0.75 mcg/ml; paired-samples t-test p < 0.001). ROC-analyses determined irisin to be predictive of treatment response (AUC = 0.741, p = 0.014).Conclusions: Irisin is positively associated with serum testosterone in a population of men with MS and LOH. TRT in these subjects has led to a significant improvement in associated clinical symptoms as well as to a significant rise in serum irisin levels.

endocrinology & metabolism,urology & nephrology
An in silico approach to elucidate the pathways leading to primary osteoporosis: age-related vs. postmenopausal

Rocío Ruiz-Lozano,José Luis Calvo-Gallego,Peter Pivonka,Michelle M. McDonald,Javier Martínez-Reina

DOI: https://doi.org/10.1007/s10237-024-01846-2

IF: 3.5

2024-05-08

Biomechanics and Modeling in Mechanobiology

Abstract:Numerical models of bone remodelling have traditionally been used to perform in silico tests of bone loss in postmenopausal women and also to simulate the response to different drug treatments. These models simulate the menopausal oestrogen decline by altering certain signalling pathways. However, they do not consider the simultaneous effect that ageing can have on cell function and bone remodelling, and thus on bone loss. Considering ageing and oestrogen decline together is important for designing osteoporosis treatments that can selectively counteract one or the other disease mechanism. A previously developed bone cell population model was adapted to consider the effect of ageing through: (1) the decrease of TGF- contained in the bone matrix and (2) an increased production of sclerostin by non-skeletal cells. Oestrogen deficiency is simulated in three different ways: (a) an increase in RANKL expression, (b) a decrease in OPG production, and (c) an increase in the responsiveness of osteoclasts to RANKL. The effect of ageing was validated using the cross-sectional study of (Riggs et al. in J Bone Miner Res 19: 1945-1954, 2004) on BMD of trabecular bone of the vertebral body of men. The joint effect of ageing and oestrogen deficiency was validated using these same clinical results but in women. In ageing, the effect of the increasing production of sclerostin is more important than the decrease of TGF- , while the three mechanisms used to simulate the effect of oestrogen deficiency produce almost identical responses. The results show that an early menopause leads to a lower average density in the fifth decade, but after the sixth decade the average density is independent of the age at menopause. Treatment of osteoporosis with denosumab was also simulated to conclude that the drug is not very effective if started before 10 years after menopause or before age 60.

engineering, biomedical,biophysics
The implications of supraphysiological testosterone supplementation

Alice T Chu,Akanksha Mehta

DOI: https://doi.org/10.1093/jsxmed/qdad179

2024-04-04

The Journal of Sexual Medicine

Abstract:Testosterone deficiency is common among aging men and causes a variety of sexual, psychological, and physical symptoms. The popularity of hormone replacement with steroids such as testosterone is relatively recent, with most literature on its effect, appropriate use, and risks published in the past 30 years. Professional society guidelines do recommend treating low testosterone in the presence of symptoms or signs of hypogonadism. Both the American Urological Association and European Academy of Andrology recommend testosterone replacement therapy to treat symptomatic testosterone deficiency, with a target testosterone level in the midnormal range. While the absolute numbers in this range may differ depending on the laboratory, the middle tertile is commonly agreed to be within the 450-600 ng/dL range. There is high-quality evidence to support testosterone correction to the eugonadal range: this range is viable for all age groups of men, and levels in this range usually ameliorate symptoms of testosterone deficiency. The TTrials, published in 2018, were a coordinated set of seven placebo-controlled, double-blind trials that investigated the efficacy of increasing testosterone levels in men with unequivocally low testosterone, and included the Sexual Function, Physical Function, Vitality, Cognitive Function, Anemia, Bone, and Cardiovascular trials. The median age of men in these trials was 72 years. All men had a baseline testosterone concentration of <275 ng/dL, which was corrected to the midnormal range for young men (approximately 500 ng/dL) for 12 months. Results showed significant improvements in all aspects of sexual function, bone mineral density, and bone strength, and moderate improvements in walking distance, mood and depressive symptoms, and anemia. 1

urology & nephrology
Testosterone and the aging male: To treat or not to treat?

Jerald Bain

DOI: https://doi.org/10.1016/j.maturitas.2010.01.009

IF: 5.11

2010-05-01

Maturitas

Abstract:It is well-established that total testosterone (TT) in men decreases with age and that bioavailable testosterone (bio-T) falls to an even greater extent. The clinical relevance of declining androgens in the aging male and use of testosterone replacement therapy (TRT) in this situation is controversial. Most studies have been short term and there are no large randomized placebo-controlled trials. Testosterone has many physiological actions in: muscles, bones, hematopoietic system, brain, reproductive and sexual organs, adipose tissue. Within these areas it stimulates: muscle growth and maintenance, bone development while inhibiting bone resorption, the production of red blood cells to increase hemoglobin, libido, enhanced mood and cognition, erectile function and lipolysis. Anabolic deficits in aging men can induce: frailty, sarcopenia, poor muscle quality, muscle weakness, hypertrophy of adipose tissue and impaired neurotransmission. The aging male with reduced testosterone availability may present with a wide variety of symptoms which in addition to frailty and weakness include: fatigue, decreased energy, decreased motivation, cognitive impairment, decreased self-confidence, depression, irritability, osteoporotic pain and the lethargy of anemia. In addition, testosterone deficiency is also associated with type-2 diabetes, the metabolic syndrome, coronary artery disease, stroke and transient ischemic attacks, and cardiovascular disease in general. Furthermore, there are early studies to suggest that TRT in men with low testosterone levels may improve metabolic status by: lowering blood sugar and HbA1C in men with type-2 diabetes, reducing abdominal girth, ameliorating features of the metabolic syndrome, all of which may be protective of the cardiovascular system. The major safety issue is prostate cancer but there is no evidence that supports the idea that testosterone causes the development of a de novo cancer. So on balance in a man with symptoms of hygonadism and low or lowish levels of testosterone with no evidence of prostate cancer such as a normal PSA a therapeutic (4-6 months) trial of TRT is justified. Treatment and monitoring of this duration will determine whether the patient is responsive.

obstetrics & gynecology,geriatrics & gerontology,gerontology
A Review on Testosterone: Estradiol Ratio-Does It Matter, How Do You Measure It, and Can You Optimize It?

Arthur L M Swislocki,Michael L Eisenberg

DOI: https://doi.org/10.5534/wjmh.240029

2024-08-30

Abstract:There is a natural balance between the major sex steroids, testosterone and estradiol, controlled by gonadal secretion and peripheral conversion by aromatase. This balance is impacted by a variety of inborn and acquired conditions, and, more recently, by a growing use of exogenous testosterone therapy and off-label aromatase use under the guise of "men's health." We summarize reported testosterone:estradiol ratios, both naturally occurring and with pharmacologic manipulation and consider the ramifications of significant changes in these ratios. However, significant limitations exist in terms of steroid separation and measurement techniques, timing of samples, and lack of consistency from one assay to another, as well as definition of normative data. Limited data on the testosterone:estradiol ratio in men exists, particularly due to the scan data on concurrent estradiol values in men receiving testosterone therapy or aromatase inhibitors. Nonetheless, there seems to be a range of apparently beneficial values of the testosterone: estradiol radio at between 10 and 30, calculated as: testosterone in ng/dL/estradiol in pg/mL. Higher values appear to be associated with improved spermatogenesis and reduced bone density while lower values are associated with thyroid dysfunction. While there is growing awareness of the significance of the testosterone:estradiol ratio, and a sense of a desired range, the optimal value has not yet been determined. Further work is needed to clarify the measurement strategies and clearly-defined outcome measures related to the testosterone:estradiol ratio.

[An unusual cause of peritonitis].

[The determination of opium alkaloids with thin layer and high pressure liquid chromatography].

Androgens, cardiovascular disease and osteoporosis

The durability and distribution of glass fibres in the rat following intra-peritoneal injection.

Association of Estrogen Receptor α and Vitamin D Receptor Gene Polymorphisms with Bone Mineral Density in Chinese Males

Biochemical characterisation of Francisella tularensis strains isolated in Spain

Early effects of androgen deprivation on bone and mineral homeostasis in adult men: a prospective cohort study.

Molecularly imprinted adsorbents for positional isomer separation.

Osteoporosis in men: the value of laboratory testing

Osteoporosis from an Endocrine Perspective: The Role of Hormonal Changes in the Elderly

Short-Term Changes in Bone Metabolism Among Transgender Men Starting Gender-Affirming Hormone Therapy: A Systematic Review and Meta-analysis

Demonstrating Adherence to Guidelines for the Treatment of Patients with Borderline Personality Disorder

The Effects of Testosterone on Bone Health in Males with Testosterone Deficiency: a Systematic Review and Meta-Analysis

The Imbalance of Cytokines and Lower Levels of Tregs in Elderly Male Primary Osteoporosis

EMAS position statement: Testosterone replacement therapy in older men

(330) Testosterone Replacement Therapy in Hypogonadism: A Single Center Longitudinal Analysis of Treatment Patterns and Clinical Outcomes

Impact of testosterone treatment on circulating irisin in men with late-onset hypogonadism and metabolic syndrome

An in silico approach to elucidate the pathways leading to primary osteoporosis: age-related vs. postmenopausal

The implications of supraphysiological testosterone supplementation

Testosterone and the aging male: To treat or not to treat?

A Review on Testosterone: Estradiol Ratio-Does It Matter, How Do You Measure It, and Can You Optimize It?